Preclinical characterization of MDL 27,192 as a potential broad spectrum anticonvulsant agent with neuroprotective properties

Epilepsy Research

Volumn 27, Issue 1, 1997, Pages 41-54

  Kehne, John H ^a,c   Kane, J Michael ^a   Chancy, Stephen F ^a   Hurst, Gail ^a   McCloskey, Timothy C ^a,c   Petty, Margaret A ^a   Senyah, Yaw ^a   Wolf, Harold H ^b   Zobrist, Ray ^a   White, H Steve ^b  

^a SANOFI   (France)

^b UNIVERSITY OF UTAH   (United States)

^c NEUROGEN CORPORATION   (United States)

Author keywords

Anticonvulsant; Epilepsy; MDL 27,192; Neuroprotection

Indexed keywords

3 MERCAPTOPROPIONIC ACID; 5 (4 CHLOROPHENYL) 4 ETHYL 2,4 DIHYDRO 2 METHYL 3H 1,2,4 TRIAZOL 3 ONE; ANTICONVULSIVE AGENT; BICUCULLINE; DIAZEPAM; MDL 27192; PENTETRAZOLE; PICROTOXIN; QUINOLINIC ACID; STRYCHNINE; UNCLASSIFIED DRUG;

ANIMAL MODEL; ANTICONVULSANT ACTIVITY; ARTICLE; ASTROCYTE; BRAIN INFARCTION; BRAIN NERVE CELL; CONTROLLED STUDY; DRUG BRAIN LEVEL; DRUG CEREBROSPINAL FLUID LEVEL; DRUG DISTRIBUTION; DRUG POTENCY; INTRAPERITONEAL DRUG ADMINISTRATION; INTRAVENOUS DRUG ADMINISTRATION; KINDLING; MALE; MOUSE; NEUROPROTECTION; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT; SEIZURE; SEIZURE THRESHOLD; SUBCUTANEOUS DRUG ADMINISTRATION;

EID: 17444446765     PISSN: 09201211     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-1211(96)01020-0     Document Type: Article

References (30)

1. Brint, S., Jacewicz, M., Kiessling, M., Tanabe, J. and Pulsinelli, W., Focal brain ischemia in the rat: Methods for reproducible neocortical infarction using tandem occlusion of the distal middle cerebral artery and ipsilateral common carotid arteries, J. Cereb. Blood Flow Metab., 8 (1988) 474-485.
2. 3H]Ro 15-1788 in mouse cerebral cortex by a series of 5-aryltriazoles, Eur. J. Pharmacol., 183 (1990) 588-589.
3. Finney, D.J., Probit Analysis, third edition, Cambridge Press, Cambridge, 1971.
4. Fujikawa, D.G., Neuroprotective effect of ketamine administered after status epilepticus onset, Epilepsia, 36 (1995) 186-195.
5. Goodman, L.S., Grewal, M.S., Brown, W.C. and Swinyard, E.A., Comparison of maximal seizures evoked by PTZ (Metrazol) and electroshock in mice, and their modification by anticonvulsants, J. Pharmacol. Exp. Ther., 108 (1953) 168-176.
6. Haley, T.J. and McCormick, W.G., Pharmacological effects produced by intracerebral injection of drugs in the conscious mouse, Br. J. Pharmacol., 12 (1957) 12-15.
7. Houser, C.R., Morphological changes in the dentate gyrus in human temporal lobe epilepsy. In: C.E. Ribak, C.M. Gall and I. Mody (Eds.), The Dentate Gyrus and Its Role in Seizures. Epilepsy Res., Suppl. 7, Elsevier, Amsterdam, 1992, pp. 223-234.
8. Kane, J.M., Baron, B.M., Dudley, M.W., Sorensen, S.M., Staeger, M.A. and Miller, F.P., 2,4-Dihydro-3H-1,2,4-triazol-3-ones as anticonvulsant agents, J. Med. Chem., 33 (1990) 272-277.
9. Kehne, J.H., Baron, B.M., Elands, J., Kane, J.M., Ogden, A.M., Rogers, C.J., Vargas, G., White, H.S., Wolf, H.H., Woodhead, J.H., McCloskey, T.C., Senyah, Y., Chaney, S.F. and Metcalf, G., MDL 27,192 5-(4-chlorophenyl)-2,4-dihydro-4-ethyl-3H-1,2,4-triazol-3-one, Soc. Neurosci. Abstr., 21 (1995a) 202.
10. Kehne, J.H., Baron, B.M., Harrison, B.L., McCloskey, T.C., Palfreyman, M.G., Poirot, M., Salituro, F.G., Siegel, B.W., Slone, A.L., van Giersbergen, P.L.M. and White, H.S., MDL 100,458 and MDL 102,288: Two potent and selective glycine receptor antagonists with different functional profiles, Eur. J. Pharmacol., 284 (1995b) 109-118.
11. 2A antagonist with a favorable CNS safety profile, J. Pharmacol. Exp. Ther., 277 (1996) 968-981.
12. Kehne, J.H., Kane, J.M., Miller, F.P., Ketteler, H.J., Braun, D.L., Senyah, Y., Chaney, S.F., Abdallah, A., Dudley, M.W., Ogden, A.M. and Palfreyman, M.G., MDL 27,531 selectively reverses strychnine-induced seizures in mice, Br. J. Pharmacol., 106 (1992) 910-916.
13. Kinnard, W.J. and Carr, C.J., A preliminary procedure for the evaluation of central nervous system depressants, J. Pharmacol. Exp. Ther., 121 (1957) 354-361.
14. Lowenstein, D.H., Thomas, M.J., Smith, D.H. and McIntosh, T.K., Selective vulnerability of dentate hilar neurons following traumatic brain injury: A potential mechanistic link between head trauma and disorders of the hippocampus, J. Neurosci., 12 (1992) 4846-4853.
15. Margerison, J. and Corsellis, J., Epilepsy and the temporal lobes, Brain, 89 (1966) 499-530.
16. Miller, F.P., Sorensen, S.M., Baron, B.M., Kane, J.M., Dudley, M.W. and Palfreyman, M.G., Inhibition of quinolinic acid seizures in mice and central hypoxic damage in gerbils by novel triazolin-3-ones, FASEB J., 2 (1988) 4501.
17. Palfreyman, M.G., Miller, F.P., Kane, J.M., Sorensen, S.M., Baron, B.M. and Dudley, M.W., MDL 27,266: A broad spectrum anticonvulsant triazol-3-one, Eur. J. Pharmacol., 183 (1990) 600-601.
18. Park, C.K., Mendelow, A.D., Graham, D.I., McCulloch, J. and Teasdale, G.M., Correlation of triphenyltetrazolium chloride perfusion staining with conventional neurohistology in the detection of early brain ischemia, Neuropathol. Appl. Neurosci., 14 (1988) 289-298.
19. Rail, T.W. and Schleifer, L.S., Drugs effective in the therapy of the epilepsies. In: A.G. Gilman, T.W. Rall, A.S. Nies and P. Taylor (Eds.), Goodman and Gilman's The Pharmacological Basic of Therapeutics, eighth edition, Pergamon Press, New York, 1990, p. 456.
20. Sheng, J.G., Shirabe, S., Nishiyama, N. and Schwartz, J.P., Alterations in stiatal glial fibrillary acidic protein expression in response to 6-hydroxydopamine-induced denervation, Exp. Brain Res., 95 (1993) 450-456.
21. Sloviter, R., Permanently altered hippocampal structure, excitability, and inhibition after experimental status epilpeticus in the rat: the 'dormant basket cell' hypothesis and its possible relevance to temporal lobe epilepsy, Hippocampus, 1 (1991) 41-66.
22. 2 antagonist MDL 100,907 as a putative atypical antipsychotic: Behavioral, electrophysiological, and neurochemical studies, J. Pharmacol. Exp. Ther., 266 (1993) 1-8.
23. Swinyard, E.A., Wolf, H.H., White, H.S., Skeen, G.A., Stark, L.G., Albertson, T., Pong, S.F. and Drust, E.G., Characterization of the anticonvulsant properties of F-721, Epilepsy Res., 15 (1993) 35-45.
24. Swinyard, E.A., Woodhead, J.H., White, H.S. and Franklin, M.R., General principles: Experimental selection, quantification, and evaluation of antiepileptics. In: R. Levy, R. Mattson, B. Meldurm, J.K. Penry and F.E. Dreifuss (Eds.), Antiepileptic Drugs, third edition, Raven Press, New York, 1989, pp. 85-102.
25. Toman, J.E.P., Swinyard, E.A. and Goodman, L.S., Properties of maximal seizures and their alteration by anticonvulsant drugs and other agents, J. Neurophysiol., 9 (1946) 231-238.
26. Turski, L., Meldrum, B.S. and Collins, J.F., Anticonvulsant action of β-kainic in mice. Is β-kainic acid an N-methyl-D-aspartate antagonist? Brain Res., 336 (1985) 162-166.
27. Vezzani, A., Wu, H-Q., Tullii, M. and Samanin, R., Anticonvulsant drugs effective against human temporal lobe epilepsy prevent seizures but not neurotoxicity induced in rats by quinolinic acid: electroencepholographic, behavioral and histological assessments, J. Pharmacol. Exp. Therap., 239 (1986) 256-263.
28. White, H.S., Patel, S. and Meldrum, B., Anticonvulsant profile of MDL 27,266: An orally active, broad spectrum anticonvulsant agent, Epilepsy Res., 12 (1992) 217-226.
29. Woodbury, L.A. and Davenport, V.D., Design and use of a new electroshock seizure apparatus, and analysis of factors altering seizure threshold and pattern, Arch. Int. Pharmacodyn. Ther., 92 (1952) 97-104.
30. Ylinen, A., Lahtinen, H., Sirvio, J., Partanen, J., Asikainen, A., Gulyas, A., Freund, T.F. and Riekkinen, P., Behavioural, electrophysiological and histopathological changes following sustained stimulation of the perforant pathway input to the hippocampus: effect of the NMDA receptor antagonist, CGP 39551, Brain Res., 553 (1991) 195-200.